Combination therapy for colorectal cancer spread to the abdomen
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of two drugs, pirfenidone and sintilimab, added to standard chemotherapy before surgery for colorectal cancer that has spread to the lining of the abdomen (peritoneal metastasis). The goal is to see if this combination helps shrink the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have colorectal cancer that has spread to the lining of your abdomen (confirmed by scan or biopsy).
- You are planning to receive your first round of chemotherapy for this condition.
- You must be in good physical condition (able to do normal daily activities with little or no help).
- Your blood counts and organ function (kidneys, liver) must be within a certain healthy range.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (anlotinib and sintilimab) as a first treatment for people with advanced colorectal cancer that has spread to places other than the liver, who do not want chemotherapy. The goal is to see if this targeted therapy can help control the cancer.
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor), growth factors, and chemotherapy (CapeOX) for people whose colorectal cancer has spread only to the liver. The goal is to see if this combination shrinks the tumors enough to allow surgery to remove them completely.
This trial tests a combination of two drugs—an injection directly into liver tumors (PIN) plus an immunotherapy (Sintilimab) given through a vein—for people with advanced colorectal cancer that has spread to the liver and has not gotten better after at least two prior treatments.
This trial tests a combination of three drugs—tucidinostat, sintilimab, and bevacizumab—for people with a specific type of advanced colorectal cancer (MSS or pMMR) that has gotten worse after standard treatments. The goal is to see if this new mix can help shrink or slow the tumor.
This trial tests a mix of three drugs (sintilimab, bevacizumab, and decitabine) for people with advanced colorectal cancer that has a stable or low amount of genetic change. It’s for those whose cancer has grown after at least two prior treatments, and who have not had immunotherapy before.
This trial tests a new combination of three drugs—fruquintinib (a targeted therapy), pirfenidone (an anti-fibrotic drug), and an immunotherapy (anti-PD-1)—for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this triple therapy can shrink tumors more effectively than current options.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.